Navigation Links
Sinovac Appoints Ernst & Young Hua Ming Llp China as External Auditor
Date:5/15/2013

BEIJING, May 15, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May 14, 2013 to replace Ernst & Young LLP Canada.

On May 14, 2013, Ernst & Young LLP Canada notified the Company that it would not stand for re-election as the Company's registered independent public accounting firm.

Both of the Company's audit committee and the board of directors have approved the appointment of Ernst & Young Hua Ming LLP to replace Ernst & Young LLP Canada. Ernst & Young Hua Ming LLP has begun providing services and is working with the Company and Ernst & Young LLP Canada to ensure a seamless transition. The Company believes that the appointment of Ernst & Young Hua Ming LLP is beneficial because of the close proximity to the Company's headquarters as the firm is also based in Beijing, China.

During the years ended December 31, 2012 and 2011, and through May 14, 2013, there were no disagreements with Ernst & Young LLP Canada on any matter of accounting principles or practices, financial statement disclosure, or auditing scope, or procedures.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. The Company recently concluded the phase III clinical trial for enterovirus 71 (against hand, foot and mouth disease). In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella, and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contact:

Helen Yang / Chris Lee
Sinovac Biotech Ltd. 
Tel: +86-10-8279-9659/ 9696
Fax: +86-10-6296-6910 
Email: ir@sinovac.com

Investors 
Stephanie Carrington 
The Ruth Group 
Tel: +1-646-536-7017 
Email: scarrington@theruthgroup.com

Media 
Victoria Aguiar 
The Ruth Group 
Tel: +1-646-536-7013 
Email: vaguiar@theruthgroup.com 


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Presents at the UBS Global Healthcare Conference in May 2013
2. Sinovac Files Annual Report on Form 20-F
3. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
4. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
5. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
6. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
7. Sinovac Holds 2012 Annual General Meeting of Shareholders
8. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
9. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
10. Sinovac Schedules 2012 Annual Meeting of Shareholders
11. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2020)... and FT. LAUDERDALE, Fla. (PRWEB) , ... February 14, 2020 , ... ... area, has joined the esteemed Haute Beauty Network. , The Haute Beauty Network, well ... Dr. Ray Lopez as a foot and ankle and our newest addition to the ...
(Date:2/15/2020)... ... , ... The creators of Dullo Plus - a premium cotton pillow ... to announce the launch of a Kickstarter campaign for 35 days starting, February 11, ... the last four years. Dullo Plus is their most advanced pillow to date , ...
(Date:2/14/2020)... , ... February 14, 2020 , ... ... medical services (EMS), fire departments and hospitals, today announced Dr. Daniel Kraft – ... of Exponential Medicine – will deliver one of three keynote presentations at ...
Breaking Medicine Technology:
(Date:2/19/2020)... , ... February 19, 2020 , ... ... Advanced Periodontics and Dental Implant Center of Connecticut, celebrate 30 years of serving ... with the same low fees that they charged in 1989, only thirty dollars. ...
(Date:2/19/2020)... ... 19, 2020 , ... MedTech IGNITE Expands Steering Committee, Faculty ... in 2020 Cohort , The Massachusetts Medical Device Industry Council ( MassMEDIC ) ... from startup founders and CEOs to participate in the 2020 IGNITE Cohort. ...
(Date:2/19/2020)... ... February 19, 2020 , ... Nvision Biomedical Technologies , ... portfolio for lower extremities at the American College of Foot and Ankle Surgeons ... Trigon® Ti Stand-Alone Osteotomy Wedge Fixation System will lead Nvision's innovative showcase. The ...
(Date:2/16/2020)... ... February 16, 2020 , ... Accumen Inc., the leader in ... and The Joint Commission to provide a complimentary series of Patient Blood Management ... and transfusion safety officers) within U.S. hospitals. , “Accumen’s mission is ...
(Date:2/15/2020)... ... February 14, 2020 , ... Sister companies, Special Learning ... “BIG MONEY IN ABA”. The series explores the challenges, risks, and opportunities of ... the series on March 25, 2020 at: https://bit.ly/2OU6lxg , Since 2010, ...
Breaking Medicine News(10 mins):